After a decades-long wait, the FDA is on the brink of approving a landmark rare disease treatment — the first to rely on a Nobel prize-winning technique known as RNA interference, or RNAi.

The widely anticipated approval will be a watershed moment not only for its manufacturer, Alnylam, but for the broader field of research into RNAi, which lets scientists mute genes that aren’t functioning properly. The FDA must announce its decision by Friday to meet a regulatory deadline.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Gee everyone will want this. The current corruption at our regulatory agencies, along with profit incentives related to “Rare Diseases” makes it the perfect time to market this product. Most of the research is Proprietary (secret) anyway. We won’t know of adverse events until long after this stuff has reached market saturation. After all those clever industry insiders believe that Healthcare is a choice, anyone desperate enough to choose to try this will only have themselves to blame.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy